89 related articles for article (PubMed ID: 1382383)
1. [Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients].
Kuriyama M; Esaki N; Yamada S; Ito S; Okano M; Takahashi Y; Shinoda I; Kawada Y; Ohkawa J; Miyawaki A
Hinyokika Kiyo; 1992 Apr; 38(4):425-31. PubMed ID: 1382383
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
[TBL] [Abstract][Full Text] [Related]
3. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer].
Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J
Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404
[TBL] [Abstract][Full Text] [Related]
4. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of serum PSA by DELFIA PSA kit and its application for mass screening. The Gunma Urological Oncology Study Group].
Imai K; Watanabe K; Higashi H; Shinya H; Okamura K; Matsuo Y; Yazima H; Takezawa Y; Yamanaka H
Hinyokika Kiyo; 1993 Sep; 39(9):807-12. PubMed ID: 7692709
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of TANDEM PSA in Japanese cases and comparison with other methods].
Kuriyama M; Yamamoto N; Shinoda I; Kawada Y; Akimoto S; Shimazaki J
Hinyokika Kiyo; 1995 Jan; 41(1):39-46. PubMed ID: 7534972
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
8. [Value of prostate-specific antigen measurements with newly developed enzyme immunoassay (MARKIT-M PA)].
Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O
Hinyokika Kiyo; 1992 Oct; 38(10):1129-34. PubMed ID: 1282772
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of Tandem-R PSA and Markit-M PA in the diagnosis of prostate cancer].
Okegawa T; Kato M; Miyata A; Murata A; Miura I; Yoneda T; Nutahara K; Higashihara E
Hinyokika Kiyo; 1999 Mar; 45(3):175-8. PubMed ID: 10331169
[TBL] [Abstract][Full Text] [Related]
11. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
12. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
13. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
[TBL] [Abstract][Full Text] [Related]
18. [Determination of free type and complex type prostate-specific antigen (PSA): differences in immunorecognition by Delfia PSA, ACS-PSA and Eiken PA kits].
Sumi S; Umeda H; Koga F; Yano M; Imai T; Hosoya Y; Honda M; Maeda S; Suzuki T; Yoshida K; Negishi T
Hinyokika Kiyo; 1996 Apr; 42(4):279-84. PubMed ID: 8693960
[TBL] [Abstract][Full Text] [Related]
19. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer.
Mochtar CA; Rahardjo D; Umbas R
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203
[TBL] [Abstract][Full Text] [Related]
20. The variation of percent free prostate-specific antigen determined by two different assays.
Yang CR; Ou YC; Horng YY; Lee HS
Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
